KIO-301
Retinitis Pigmentosa (Mutation Agnostic)
Key Facts
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotech focused on developing advanced small molecule therapies for retinal diseases with high unmet need. Its strategy is built on two distinct platforms: KIO-301, a first-in-class 'photoswitch' molecule designed to restore vision in inherited retinal diseases by converting dormant retinal cells into light sensors, and KIO-104, an immune modulator for inflammatory conditions like proliferative vitreoretinopathy (PVR). The company has achieved key regulatory milestones, including Orphan Drug designations for both lead assets, and is advancing its pipeline through strategic partnerships and clinical trials.
View full company profileAbout Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotech focused on developing advanced small molecule therapies for retinal diseases with high unmet need. Its strategy is built on two distinct platforms: KIO-301, a first-in-class 'photoswitch' molecule designed to restore vision in inherited retinal diseases by converting dormant retinal cells into light sensors, and KIO-104, an immune modulator for inflammatory conditions like proliferative vitreoretinopathy (PVR). The company has achieved key regulatory milestones, including Orphan Drug designations for both lead assets, and is advancing its pipeline through strategic partnerships and clinical trials.
View full company profileAbout Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotech focused on developing advanced small molecule therapies for retinal diseases with high unmet need. Its strategy is built on two distinct platforms: KIO-301, a first-in-class 'photoswitch' molecule designed to restore vision in inherited retinal diseases by converting dormant retinal cells into light sensors, and KIO-104, an immune modulator for inflammatory conditions like proliferative vitreoretinopathy (PVR). The company has achieved key regulatory milestones, including Orphan Drug designations for both lead assets, and is advancing its pipeline through strategic partnerships and clinical trials.
View full company profile